BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34735935)

  • 1. Prognostic significance of ATM mutations in chronic lymphocytic leukemia: A meta-analysis.
    Baghaei Vaji F; Boroumand Nasr A; Rezvani A; Ayatollahi H; Goudarzi S; Lavasani S; Bagheri R
    Leuk Res; 2021 Dec; 111():106729. PubMed ID: 34735935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomere length and its correlation with gene mutations in chronic lymphocytic leukemia in a Korean population.
    Song DY; Kim JA; Jeong D; Yun J; Kim SM; Lim K; Park SN; Im K; Choi S; Yoon SS; Lee DS
    PLoS One; 2019; 14(7):e0220177. PubMed ID: 31335885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.
    Austen B; Powell JE; Alvi A; Edwards I; Hooper L; Starczynski J; Taylor AM; Fegan C; Moss P; Stankovic T
    Blood; 2005 Nov; 106(9):3175-82. PubMed ID: 16014569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion.
    Lozano-Santos C; García-Vela JA; Pérez-Sanz N; Nova-Gurumeta S; Fernandez-Cuevas B; Gomez-Lozano N; Sánchez-Beato M; Sanchez-Godoy P; Bueno JL; Garcia-Marco JA
    Leuk Lymphoma; 2017 Apr; 58(4):859-865. PubMed ID: 27499002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia.
    Ouillette P; Li J; Shaknovich R; Li Y; Melnick A; Shedden K; Malek SN
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1125-32. PubMed ID: 22952040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.
    Stankovic T; Stewart GS; Fegan C; Biggs P; Last J; Byrd PJ; Keenan RD; Moss PA; Taylor AM
    Blood; 2002 Jan; 99(1):300-9. PubMed ID: 11756185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.
    Stankovic T; Skowronska A
    Leuk Lymphoma; 2014 Jun; 55(6):1227-39. PubMed ID: 23906020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.
    Navrkalova V; Sebejova L; Zemanova J; Kminkova J; Kubesova B; Malcikova J; Mraz M; Smardova J; Pavlova S; Doubek M; Brychtova Y; Potesil D; Nemethova V; Mayer J; Pospisilova S; Trbusek M
    Haematologica; 2013 Jul; 98(7):1124-31. PubMed ID: 23585524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.
    Blakemore SJ; Clifford R; Parker H; Antoniou P; Stec-Dziedzic E; Larrayoz M; Davis Z; Kadalyayil L; Colins A; Robbe P; Vavoulis D; Forster J; Carr L; Morilla R; Else M; Bryant D; McCarthy H; Walewska RJ; Steele AJ; Chan J; Speight G; Stankovic T; Cragg MS; Catovsky D; Oscier DG; Rose-Zerilli MJJ; Schuh A; Strefford JC
    Leukemia; 2020 Jul; 34(7):1760-1774. PubMed ID: 32015491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
    Skowronska A; Parker A; Ahmed G; Oldreive C; Davis Z; Richards S; Dyer M; Matutes E; Gonzalez D; Taylor AM; Moss P; Thomas P; Oscier D; Stankovic T
    J Clin Oncol; 2012 Dec; 30(36):4524-32. PubMed ID: 23091097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
    Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
    Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.
    Athanasakis E; Melloni E; Rigolin GM; Agnoletto C; Voltan R; Vozzi D; Piscianz E; Segat L; Dal Monego S; Cuneo A; Secchiero P; Zauli G
    Oncotarget; 2014 Dec; 5(24):12635-45. PubMed ID: 25587027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The p53 pathway induction is not primarily dependent on Ataxia Telangiectasia Mutated (ATM) gene activity after fludarabine treatment in chronic lymphocytic leukemia cells.
    Navrkalova V; Sebejova L; Zemanova J; Jaskova Z; Trbusek M
    Leuk Lymphoma; 2013 Aug; 54(8):1840-3. PubMed ID: 23808769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.
    Jafari PA; Sadeghian MH; Miri HH; Sadeghi R; Bagheri R; Lavasani S; Souri S
    Crit Rev Oncol Hematol; 2020 Jan; 145():102832. PubMed ID: 31812130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
    Lozanski G; Ruppert AS; Heerema NA; Lozanski A; Lucas DM; Gordon A; Gribben JG; Morrison VA; Rai KM; Marcucci G; Larson RA; Byrd JC
    Leuk Lymphoma; 2012 Sep; 53(9):1743-8. PubMed ID: 22369572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
    Nabhan C; Raca G; Wang YL
    JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.
    te Raa GD; Moerland PD; Leeksma AC; Derks IA; Yigittop H; Laddach N; Loden-van Straaten M; Navrkalova V; Trbusek M; Luijks DM; Zenz T; Skowronska A; Hoogendoorn M; Stankovic T; van Oers MH; Eldering E; Kater AP
    Cell Death Dis; 2015 Aug; 6(8):e1852. PubMed ID: 26247737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between ATM gene polymorphisms, lung cancer susceptibility and radiation-induced pneumonitis: a meta-analysis.
    Yan Z; Tong X; Ma Y; Liu S; Yang L; Yang X; Yang X; Bai M; Fan H
    BMC Pulm Med; 2017 Dec; 17(1):205. PubMed ID: 29246212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of SF3B1 mutations in CLL on the DNA-damage response.
    Te Raa GD; Derks IA; Navrkalova V; Skowronska A; Moerland PD; van Laar J; Oldreive C; Monsuur H; Trbusek M; Malcikova J; Lodén M; Geisler CH; Hüllein J; Jethwa A; Zenz T; Pospisilova S; Stankovic T; van Oers MH; Kater AP; Eldering E
    Leukemia; 2015 May; 29(5):1133-42. PubMed ID: 25371178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.